维奈克拉治疗后慢性淋巴细胞白血病的处理策略
本文综述维奈克拉耐药生物学机制及治疗后进展的临床场景。维奈克拉方案可诱导深度缓解并实现限时治疗,但复发难治尤其TP53异常患者常见耐药进展。进展后可选BCR通路抑制剂、异基因移植、CAR-T或限时治疗后复发者维奈克拉再治疗,但决策数据有限。
要点
- 维奈克拉方案可实现深缓解和限时治疗,但复发难治及TP53异常者常见耐药进展。
- 耐药机制包括BCL2突变、替代BCL2家族蛋白上调及基因组不稳定。
- 维奈克拉后进展可选BCR通路抑制剂、异基因移植、CAR-T或再治疗,但证据有限。
核心结论
- 维奈克拉方案提高CLL疗效并可限时治疗,但复发难治尤其TP53异常患者常见耐药进展。
- 维奈克拉耐药表现为寡克隆白血病群体及多种耐药机制,Richter转化是独特挑战。
- 维奈克拉后进展的治疗选择包括BCR通路抑制剂、异基因移植、CAR-T及再治疗,但决策数据有限。
研究设计与样本
- 本文为综述,回顾维奈克拉耐药生物学并概述维奈克拉治疗后常见临床场景的处理方法。
主要发现
- 维奈克拉方案常实现不可测残留病缓解并支持无化疗限时治疗。
- 复发难治尤其TP53异常患者长期随访显示频繁耐药和进展。
- 进展疾病典型表现为寡克隆白血病群体,伴BCL2突变、替代BCL2家族蛋白上调及基因组不稳定。
- Richter转化多见于氟达拉滨难治且复杂核型的重度预处理患者,是维奈克拉耐药的独特表现。
关键数值与推荐
- 维奈克拉后进展可选BCR通路抑制剂、异基因造血干细胞移植、CAR-T,限时治疗后复发者可维奈克拉再治疗。
临床怎么用
- 维奈克拉治疗后进展患者需评估耐药机制及Richter转化,个体化选择BCR抑制剂、移植、CAR-T或再治疗。
局限性
- 维奈克拉耐药理解仍不完整。
- 指导维奈克拉后进展患者临床决策的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax-based regimens have expanded the therapeutic options for patients with chronic lymphocytic leukemia (CLL), frequently achieving remissions with undetectable measurable residual disease and facilitating time-limited treatment without chemotherapy. Although response rates are high and durable disease control is common, longer-term follow-up of patients with relapsed and refractory disease, especially in the presence of TP53 aberrations, demonstrates frequent disease resistance and progression. Although the understanding of venetoclax resistance remains incomplete, progressive disease is typified by oligoclonal leukemic populations with distinct resistance mechanisms, including BCL2 mutations, upregulation of alternative BCL2 family proteins, and genomic instability. Although most commonly observed in heavily pretreated patients with disease refractory to fludarabine and harboring complex karyotype, Richter transformation presents a distinct and challenging manifestation of venetoclax resistance. For patients with progressive CLL after venetoclax, treatment options include B-cell receptor pathway inhibitors, allogeneic stem cell transplantation, chimeric antigen receptor T cells, and venetoclax retreatment for those with disease relapsing after time-limited therapy. However, data to inform clinical decisions for these patients are limited. We review the biology of venetoclax resistance and outline an approach to the common clinical scenarios encountered after venetoclax-based therapy that will increasingly confront practicing clinicians.
引用
- Lew TE, Tam CS, Seymour JF, et al. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021. PMID: 33876212. doi:10.1182/blood.2020008502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。